Accomplished pharmaceutical leader in infectious diseases Nkechi Azie joins GAFFI Board.

Posted .

Nkechi (Mbanefo) Azie MD MBA FIDSA

GAFFI is pleased to announce that Nkechi (Mbanefo) Azie MD MBA FIDSA, a highly accomplished pharmaceutical executive, has joined the GAFFI Board of Directors. Dr. Azie is widely recognized as an expert in the field of infectious diseases with breadth of experience in translational medicine, drug development, medical affairs, product launches, and pharmacovigilance. She has held key leadership roles in the clinical development of major antifungals and antibiotics for Astellas, Pfizer, The Medicines Company, and, most recently, Scynexis. She has broad experience that also covers vaccines, immunology, neurology, gastrointestinal disease, and women’s health. Dr. Azie has extensive experience interacting with the FDA and other global regulatory agencies to deliver safe and effective products at the global level. She has successfully led product Lifecycle management strategies to optimize product value to patients, payers, and companies. Dr. Azie, a native of Nigeria, obtained her medical degree at the University of Nigeria. She did her medical/infectious diseases residency training at Indiana University and obtained an MBA from Notre Dame University.  Currently, she is the Global Chief Medical Officer for SymBio Pharmaceuticals

GAFFI’s Board now consists of David Perlin, Skhumbuzo Ngozwana, Dave Allmond, Juan Luis Rodriguez-Tudela, Yasuaki Mori, and Oddi Aasheim. Read more about GAFFI’s transformation and new strategy here.